DWA
AVDL

Dorsey Wright & Associates’s Avadel Pharmaceuticals AVDL Stock Holding History

Dorsey Wright & Associates’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-142,120
Closed -$1.86M – 131
2024
Q3 		$1.86M Buy
142,120
+16,215
+13% +$247K 0.44% 94
2024
Q2 		$1.77M Sell
125,905
-1,735
-1% -$28.3K 0.46% 94
2024
Q1 		$2.16M Buy
+127,640
New +$1.9M 0.56% 84
2015
Q4 		– Sell
-17,732
Closed -$289K – 108
2015
Q3 		$289K Buy
17,732
+3,212
+22% +$70.7K 0.15% 79
2015
Q2 		$287K Buy
14,520
+1,658
+13% +$29.7K 0.14% 82
2015
Q1 		$231K Sell
12,862
-27
-0.2% -$423 0.11% 91
2014
Q4 		$221K Buy
12,889
+1,985
+18% +$28.3K 0.1% 105
2014
Q3 		$156K Sell
10,904
-809
-7% -$11.6K 0.02% 121
2014
Q2 		$160K Buy
11,713
+161
+1% +$1.94K 0.02% 137
2014
Q1 		$135K Buy
+11,552
New +$124K 0.02% 133

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Dorsey Wright & Associates's AVDL Position: Q4 2024 in Review

Dorsey Wright & Associates sold out of Avadel Pharmaceuticals (AVDL) in Q4 2024, closing a stake of 142,120 shares — an estimated $1.86M sold.

Dorsey Wright & Associates first reported a position in AVDL in Q1 2014 and held it in 10 quarters. The position peaked at $2.16M in Q1 2024. 159 funds tracked by Wall St. Rank hold AVDL as of Q4 2024.

  • Dorsey Wright & Associates reported no remaining Avadel Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Dorsey Wright & Associates sold 142,120 Avadel Pharmaceuticals shares in Q4 2024, an estimated $1.86M.
  • Dorsey Wright & Associates first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 10 quarters.
  • Dorsey Wright & Associates's Avadel Pharmaceuticals position peaked at $2.16M in Q1 2024.
  • 159 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2024.

Based on Dorsey Wright & Associates's 13F filing for Q4 2024, filed 12 Feb 2025.